A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1

Новый терапевтический подход к лечению анапластического рака щитовидной железы посредством ингибирования LAT1
Naoyoshi Onoda, Shinya Uchino, Muneki Hotomi, Keisuke Enomoto, Fuyuki Sato, Shunji Tamagawa, Mehmet Gündüz, Yasuteru Muragaki
2019-10-10

JPH203LAT1 inhibitoranaplastic thyroid cancermTOR signalingxenograft model
A novel therapeutic approach is urgently needed for patients with anaplastic thyroid cancer (ATC) due to its fatal and rapid progress. We recently reported that ATC highly expressed MYC protein and blocking of MYC through its selective inhibitor, JQ1, decreased ATC growth and improved survival in preclinical models. One of the important roles of MYC is regulation of L-neutral amino acid transporter 1 (LAT1) protein and inhibition of LAT1 would provide similar anti-tumor effect. We first identified that while the human ATC expresses LAT1 protein, it is little or not detected in non-cancerous thyroidal tissue, further supporting LAT1 as a good target. Then we evaluated the efficacy of JPH203, a LAT1 inhibitor, against ATC by using the in vitro cell-based studies and in vivo xenograft model bearing human ATC cells. JPH203 markedly inhibited proliferation of three ATC cell lines through suppression of mTOR signals and blocked cell cycle progression from the G0/G1 phase to the S phase. The tumor growth inhibition and decrease in size by JPH203 via inhibition of mTOR signaling and G0/G1 cell cycle associated proteins were further confirmed in xenograft models. These preclinical findings suggest that LAT1 inhibitors are strong candidates to control ATC, for which current treatment options are highly limited.
1
In human anaplastic thyroid cancer xenograft models, JPH203 inhibited tumor growth and reduced tumor size through effects on mTOR signaling and G0/G1 cell-cycle-associated proteins.
2
JPH203 blocked anaplastic thyroid cancer cell-cycle progression from the G0/G1 phase to the S phase.
3
LAT1 protein is highly expressed in human anaplastic thyroid cancer but is minimally or undetectable in non-cancerous thyroid tissue, supporting LAT1 as a therapeutic target.
4
The LAT1 inhibitor JPH203 markedly inhibited proliferation across three anaplastic thyroid cancer cell lines by suppressing mTOR signaling.
5
These preclinical results identify LAT1 inhibitors as promising candidates for treating anaplastic thyroid cancer, which has limited effective therapies.

anaplastic thyroid cancer (ATC) cells and xenograft tumors

the antitumor efficacy and mechanisms of LAT1 inhibition, including suppression of mTOR signaling and G0/G1-to-S cell-cycle progression

Publication Details
Publication Date
2019-10-10
Journal
Publisher
ISSN
Cited by
56
Access Type
Author Information
Authors
Naoyoshi Onoda
Shinya Uchino
Muneki Hotomi
Keisuke Enomoto
Fuyuki Sato
Shunji Tamagawa
Mehmet Gündüz
Yasuteru Muragaki
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%